Loading menubar.....

Difference between revisions of "Team:Munich/workspace/Alex"

 
Line 870: Line 870:
 
<div class="col-12">
 
<div class="col-12">
 
<h4 >ALiVE is online</h4>
 
<h4 >ALiVE is online</h4>
−
     <p font-family: 'Open Sans', sans-serif;>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.</p>
+
     <p font-family: 'Open Sans', sans-serif;>After we decided on two vesicles and figured theoretically out how we want to load our vesicles specifically for our non-invasive cell monitoring approach we performed the experiments necessary to proof the functionality of our system. For those who are interested in the exact constructions of our vesicles can find a detailed plan at “Model”. In short we use the following two vesicle types:
 +
1. Exosomes: a naturally occurring secretion pathway of cells to get rid of different materials like cellular trash but also valuable information for other cells.
 +
2. Virus-like particles (VLPs): artificially produced vesicle type that can be used as extracellular vesicle to export information.
 +
Our vesicles are non-toxic and can load very specific information depending on what we want to analyze and monitor.
 +
</p>
 
</div>
 
</div>
 
</div>
 
</div>

Latest revision as of 18:49, 7 September 2019

<!DOCTYPE html> Team:Munich/workspace/framework - 2019.igem.org

Loading menubar.....

Team:Munich/workspace/framework

Alive

ALiVE

Analysis of Living Cells by Vesicular Export

A generic square placeholder image with rounded corners in a figure.

Results

ALiVE is online

After we decided on two vesicles and figured theoretically out how we want to load our vesicles specifically for our non-invasive cell monitoring approach we performed the experiments necessary to proof the functionality of our system. For those who are interested in the exact constructions of our vesicles can find a detailed plan at “Model”. In short we use the following two vesicle types: 1. Exosomes: a naturally occurring secretion pathway of cells to get rid of different materials like cellular trash but also valuable information for other cells. 2. Virus-like particles (VLPs): artificially produced vesicle type that can be used as extracellular vesicle to export information. Our vesicles are non-toxic and can load very specific information depending on what we want to analyze and monitor.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

First Element:

Subtitle?

  • 1
  • 2
  • 3

Second Element:

  • 1
  • 2

Third Element:

Stuff

  • 1

Fourth Element

  • 1
  • 2

Fullscreen Pic

A generic square placeholder image with rounded corners in a figure.

Half Half

A generic square placeholder image with rounded corners in a figure.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Different Background Box

ALiVE is online

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Our greatest glory is not in never falling, but in rising every time we fall.

Confucius

Video

Materials Price for a single reaction (15µl) Price per patient
Buffer + Media $0.19 $0.13
Energy Solution $2.99 $1.99
Phage DNA $0.07 $0.05
Work $0.76 $0.50
Total $4.01 $2.67

Half Half Alt Background

A generic square placeholder image with rounded corners in a figure.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

References

  1. Centers for Disease Control and Prevention, 2017. Antibiotic/Antimicrobial Resistance.
  2. ECDC Data and reports: Antimicrobial resistance and consumption, 2017
  3. Liu, Y.-Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161–168 (2016).
  4. Barriere, S. L. Clinical, economic and societal impact of antibiotic resistance. Expert Opin. Pharmacother. 16, 151–153 (2015).
  5. Dierig, A., Frei, R. & Egli, A. The fast route to microbe identification: matrix assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). Pediatr. Infect. Dis. J. 34, 97–9 (2015).
  6. Ng, E. W. Y., Wong, M. Y. M. & Poon, T. C. W. in 139–175 (Springer, Berlin, Heidelberg, 2013).
  7. Theriot, C. M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5, 3114 (2014).
  8. Międzybrodzki, R. et al. Clinical Aspects of Phage Therapy. Adv. Virus Res. 83, 73–121 (2012).
  9. Henry, M., Lavigne, R. & Debarbieux, L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961–8 (2013).
  10. Pirnay, J.-P. et al. The Magistral Phage. Viruses 10, 64 (2018).
  11. Gill, J., & Hyman, P. (2010). Phage Choice, Isolation, and Preparation for Phage Therapy. Current Pharmaceutical Biotechnology, 11(1), 2–14.
  12. Fortier, L.-C. & Sekulovic, O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4, 354–365 (2013).
  13. Fauconnier, A. in 253–268 (Humana Press, New York, NY, 2018). doi:10.1007/978-1-4939-7395-8_19
  14. Navarro-Garcia, F. Escherichia coli O104:H4 Pathogenesis: an Enteroaggregative E. coli/Shiga Toxin-Producing E. coli Explosive Cocktail of High Virulence. Microbiol. Spectr. 2, (2014).
  15. Colom, J. et al. Microencapsulation with alginate/CaCO3: A strategy for improved phage therapy. Sci. Rep. 7, 41441 (2017).